Quanterix to Present at The LEERINK Partners 7th Annual Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chief Executive Officer, President and Chairman, Kevin Hrusovsky, will be presenting at the LEERINK Partners 7th Annual Global Healthcare Summit. The presentation will take place on Thursday, February 15, at 10:00 a.m. EST in New York City.

To access the live webcast of Quanterix’ presentation please visit the News & Events page within the Investors section of the Quanterix website at http://www.quanterix.com/. Replays of the webcast will be available on the Quanterix website for 90 days following the conference.

About Quanterix
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to Simoa’s potential ability to change the way in which healthcare is provided today and the ability of Quanterix’ technology to enable much earlier disease detection, better prognoses and enhanced treatment methods, and are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts

PAN Communications
Lauren Kaufman, 617-502-4300
quanterix@pancomm.com